VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix, Inc. (OTCBB:PKTX) announced the latest cryopreservation
results using mouse embryonic stem cells preserved at -80°C
for 2 days and rapidly thawed to assay for viability. PKTX is currently
in discussion with several corporations and Research Institutes about
the commercialization of AAGP™ in the
application of cryopreservation of cell lines and we are pleased to
report the following results:
Based on previous experiments using stem cells, concentrations of AAGP™
were varied to obtain the lowest and most optimal concentrations.
i.)
control - 10% Dimethyl Sulfoxide (DMSO)
66% viability
ii.)
1mg/ml of AAGPTM 1-J +10% DMSO
89% viability
iii.)
5mg/ml of AAGPTM 1-J + 10% DMSO
96% viability
iv.)
4.4mg/ml of AAGPTM 5-F + 10% DMSO
100% viability
These experiments clearly demonstrate that AAGP™
concentrations can be lowered while maintaining close to the full
potential of the molecule with regards to cryopreservation. These
results confirm a substantial benefit in the preservation of expensive
cell lines and tissue, clearly meeting a need in research, industry and
medicine.
About ProtoKinetix:
ProtoKinetix, Inc. is a Biotechnical Company dedicated to the
development of a family of synthetic antifreeze glycoproteins (AAGP™)
for human and veterinary medicine and the biotechnology and cosmetic
industries. Using previously published research on native antifreeze
proteins and antifreeze glycoproteins as a guide, and coordinating a
vast pool of world-recognized intellectual talent in a networked
environment, PKTX is conducting rapid and meaningful research with a
view to developing markets for this very useful family of molecules.
Sign up for free automatic email news alerts at our new website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a “safe
harbor” for forward-looking statements. Some
information included in this press release contains statements that are
forward looking. Such forward-looking information involves significant
risks and uncertainties that could affect anticipated results in the
future and, accordingly, these results may differ materially from those
expressed in any forward-looking statements made by or on behalf of the
Company. For a description of additional risks and uncertainties, please
refer to the Company’s filings with the
Securities and Exchange Commission.
